# SAbR For Oligometastatic Renal Cell Carcinoma

> **NCT02956798** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Oligometastatic Renal Cell Carcinoma

## Interventions

- **RADIATION:** Stereotactic ablative body radiation (SABR)

## Key facts

- **NCT ID:** NCT02956798
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-19
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02956798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02956798, "SAbR For Oligometastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02956798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*